GlassScriptPhysician profile
Bruce Allen Barton
NPI 1194793505
$888.79
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $233.37 | 2019 | |
| Genentech USA, INC. | $137.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $136.67 | 2019 | |
| Grifols USA, LLC | $114.81 | 2019 | |
| Mylan Specialty L.P. | $66.10 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $60.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.16 | 2019 | |
| Shire North American Group INC | $31.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.75 | 2019 | |
| Optinose US, INC. | $17.36 | 2019 | |
| Insmed, INC. | $16.16 | 2019 | |
| Circassia INC. | $10.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.